

LIFTMODE 47 W. Polk St. STE 100-241 Chicago, IL 60605 liftmode@liftmode.com www.liftmode.com

CERTIFICATE OF ANALYSIS

Oleamide

(Oleic Acid Amide)

Material Lot #: 0001487711 Manufacture Date: 04/14/2019
Country of Origin: United Kingdom Testing Date: 12/21/2019
Retesting Date: 12/20/2022

Analysis Claim Result

Total Fatty Acid Amide ≥98.0% 99.39%


| Test | Specification | Result |
|----------------|-----------------------------|------------|
| Appearance | Small prill or powder | Complies |
| Melting Point | 72-77°C | 73.5°C |
| Amide Purity | <u>></u> 98% | 99.39% |
| Acid Value | <u><</u> 0.8 mg KOH/g | 0.45 KOH/g |
| Iodine Value | 80-95 gl ₂ /100g | 86.7 |
| Color (hazen) | <u><</u> 400 | 150 |
| Moisture (wt%) | <u><</u> 0.1 | 0.04 |

Oleamide should be refrigerated in a tightly sealed durable container. Oleamide should be protected from excess heat, direct sunlight, excess humidity and moisture. Oleamide has a testing period of 3 years from the date of testing when properly stored.

LIFTMODE

LIFTMODE 47 W. Polk St. STE 100-241 Chicago, IL 60605 liftmode@liftmode.com www.liftmode.com

OLEAMIDE



Main Benefits

- Oleamide is a naturally-occurring compound that is produced from oleic acid and is known to accumulate in the brain prior to sleep.
- Benefits of Oleamide include the ability to support healthy stress levels, promotion of healthy sleeping patterns as well as an increase in appetite.
- Oleamide is known to enhance GABA receptor signalling, which is associated with improvements in mood and stress-reduction.

Main Cautions

- It is not recommended to exceed the suggested serving size for Oleamide due to the relatively low number of human studies on this supplement.
- Oleamide is associated with a decline in locomotive function even at medium doses so users should not attempt to drive or to operate heavy machinery.
- Please speak to your doctor before using Oleamide if you have any pre-existing medical conditions or are taking any medication

Usage Tips

- A 0.15cc measuring scoop is included. One level scoop contains approximately one serving, or approximately 50 mg of Oleamide. As a dietary supplement, take 1-8 servings 1-2 times per day. Start at the lower suggested quantity to assess response.
- The negative effects of Oleamide are dependent on the amount taken, so use of a scale with 10mg/0.01g accuracy or better is highly recommended.
- Use of capsules, or mixing with tea, yogurt, apple sauce, or oatmeal may help make the powder more tolerable
- This supplement is not intended to treat, diagnose, prevent, or cure any diseases. Consult your healthcare provider before use if you have a medical condition or if you are taking any prescription medications.
- It is safe to stack Oleamide with other supplements, so long as the amount consumed does not exceed the suggested serving size.
- The benefits of Oleamide are most effective when they are supported by a healthy diet and plenty of everyise.



812 Meadow Lark Lane, Godlettsville, TN 37072 Telephone: 615-239-8604

Certificate of Analysis

Synaptent LLC 47 W Polk Street, 100-241 Chicago, IL 60654

| Product Name | Oleamide | Client Lot Number | 0001487711 |
|--------------|----------|-------------------|------------|
| Report Date | 12/21/19 | Laboratory Number | 13450 |

| Test | Method | Result |
|------------------------------|------------------|-------------|
| Oleamide | HPLC | 67.7% |
| Amide and Fatty acid content | HPLC | 100.4% |
| Lead | ICP-MS USP <730> | 0.007 ppm |
| Arsenic | ICP-MS USP <730> | <0.0001 ppm |
| Cadmium | ICP-MS USP <730> | 0.010 ppm |
| Mercury | ICP-MS USP <730> | 0.013 ppm |
| Total Aerobic count | Biolumix | <100 cfu/g |
| Yeast and Mold | Biolumix | <100 cfu/g |
| E. Coli | Biolumix | Negative |
| Coliform | Biolumix | <10 cfu/g |
| Salmonella | Biolumix | Negative |

Collin Thomas MX
Laboratory Manager

12/21/2019 12/u |

The result(s) stated in this report is only for the sample submitted. This report may not be reproduced in whole or in part, nor may any reference be made to the work, the result, or the company in any news release, public announcements or advertising without our prior written consent.